PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL

Journal of Cellular Physiology

Volumn 214, Issue 1, 2008, Pages 192-200

  Caravatta, Luciana ^a   Sancilio, Silvia ^a   Di Giacomo, Viviana ^a   Rana, Rosalba ^a   Cataldi, Amelia ^a   Di Pietro, Roberta ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SB 253580; SERINE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIBODY LABELING; APOPTOSIS; ARTICLE; CELL COMPARTMENTALIZATION; CELL CULTURE; CELL DEATH; CYTOPLASM; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CASPASE 3; CELL CULTURE TECHNIQUES; CHROMONES; CLONE CELLS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FLUORESCENT DYES; HISTIDINE; HUMANS; IMIDAZOLES; INDOLES; JURKAT CELLS; LEUKEMIA; MORPHOLINES; NECROSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION;

EID: 36849074803     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21186     Document Type: Article

References (48)

1. Armitage RJ. 1994. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 6:407-413.
2. Baker SJ, Reddy RP. 1996. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 12:1-9.
3. Barton K, Muthusamy N, Chanyanggam M, Fischer C, Cledenin C, Leiden JM. 1996. Defective thymocytes proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature 379:81-84.
4. Brindle PT, Nakajima T, Montminy M. 1995. Multiple Protein kinase A regulated events are required for transcriptional induction by cAMP. Proc Natl Acad Sci USA 92:10251-10254.
5. Choi SC, Kim BS, Song MY, Choi EY, Oh HM, Lyou JH, Han WC, Moon HB, Kim TH, Oh JM, Chung HT, Jun CD. 2003. Down-regulation of p38 kinase pathway by cAMP Response Element Binding Protein protects HL-60 cells from iron chelator-induced apoptosis. Free Radic Biol Med 35:1171-1184.
6. Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G, Gadner H, Younes A. 2000. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 111:580-586.
7. De Cesare D, Jacquot S, Hanauer A, Sassone-Corsi P. 1998. RSK-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc Natl Acad Sci USA 95:12202-12207.
8. Deak M, Clifton AD, Lucocq JM, Alessi DR. 1998. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK/p38, and may mediate activation of CREB. EMBO J 17:4426-4441.
9. Delghandi MP, Johannessen M, Moens U. 2005. The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell Signal 17:1343-1351.
10. Di Pietro R, Zauli G. 2004. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/Apo-2L. J Cell Physiol 201:331-340.
11. Di Pietro R, Secchiero P, Rana RA, Gibellini D, Visani G, Bemis R, Zamai L, Miscia S, Zauli G. 2001. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumour necrosis factor apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAL- R1. Blood 97:2596-2603.
12. Di Pietro R, di Giacomo V, Caravatta L, Sancilio S, Rana RA, Cataldi A. 2007. Cyclic nucleotide response element binding protein (CREB) protein activation is involved in K562 erythroleukemia cells differentiation. J Cell Biochem 100:1070-1079.
13. Du K, Montminy M. 1998. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273:32377-32379.
14. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. 2003. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 22:3842-3852.
15. Foulkes NS, Laoide BM, Schlotter F, Sassone-Corsi P. 1991. Transcriptional antagonist cAMP-responsive element modulator (CREM) down-regulates c-fos cAMP-induced expression. Proc Natl Acad Sci USA 88:5448-5452.
16. Fox KE, fankell DM, Erickson PF, Majka SM, Crossna JT, Jr., Klemm DJ. 2006. Depletion of cAMP-response element-binding protein/ATF1 inhibits adipogenic conversion of 3T3-L1 cells ectopically expressing CCAAT/enhancer-binding protein (C/EBP) α, C/EBP β, or PPAR γ2. J Biol Chem 281:40341-40353.
17. Gibellini D, Bassini A, Pierpaoli S, Bertolaso L, Milani D, Capitani S, La Placa M, Zauli G. 1998. Extracellular HIV-1 Tat protein induces the rapid ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid t cells and primary peripheral blood mononuclear cells. J Immunol 160:3891-3898.
18. Ivanov VN, Bhoumik A, Ronai Z. 2003. Death receptors and melanoma resistance to apoptosis. Oncogene 22:3152-3161.
19. Jang YJ, Park KS, Chung HY, Kim HI. 2003. Analysis of the phenotypes of Jurkat clones with different TRAIL sensitivities. Cancer Lett 194:107-117.
20. Jean D, Harbison M, McConkey DJ, Ronai Z, Bar-Eli M. 1998. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem 273:24884-24890.
21. Jean D, Tellez C, Huang S, Davis DW, Bruns CJ, McConkey DJ, Hinrichs SH, Bar-Eli M. 2000. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene 19:2721-2730.
22. Johannessen M, Delghandi MP, Moens U. 2004. What turns CREB on? Cell Signal 16:1211-1227.
23. Kutuk O, Pedrech A, Harrison P, Basaga H. 2005. Pramanicin induces apoptosis in Jurkat leukemia cells: a role for JNK, p38 and caspase activation. Apoptosis 10:597-609.
24. Laffargue M, Raynal P, Yart A, Peres C, Wetzker R, Roche S, Payrastre B, Chap H. 1999. An epidermal growth factor receptor/Gab1 signalling pathway is required for activation of PI-3-kinase by lysophosphatidic acid. J Biol Chem 274:32835-32841.
25. Meyer TE, Habener JF. 1993. Cyclic adenosine 3′,5′- monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocrinol Rev 14:269-290.
26. Migliaccio G, Di Pietro R, di Giacomo V, Di Baldassare A, Migliaccio AR, Maccioni L, Galanello R, Papayannopoulou T. 2002. In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cell Mol Dis 28:169-180.
27. Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, Capitani S, Secchiero P. 2003. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126-135.
28. Morel J, Audo R, Hahne M, Combe B. 2005. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 280:15709-15718.
29. Muhlenbeck F, Haas E, Schwenzer R, Grell M, Smith C, Scheurich P, Waiant H. 1998. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem 273:33091-33098.
30. Nantel F, Sassone-Corsi P. 1996. CREM: A transcriptional master switch during the spermatogenesis differentiation program. Front Biosci 1:266-269.
31. Ponti C, Gibellini D, Boin F, Melloni E, Manzoli FA, Cocco L, Zauli G, Vitale M. 2002. Role of CREB transcription factor in c-fos activation in natural killer cells. Eur J Immunol 32:3358-3365.
32. Radhakrishnan I, Perez-Alvarado GC, Parker D, Dyson HJ, Montminy MR, Wright PE. 1997. Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: A model for activator:coactivator interactions. Cell 91:741-752.
33. Rehfuss RP, Walton KM, Loriaux MM, Goodman RH. 1991. The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A. J Biol Chem 266:18431-18434.
34. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. 2002. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces monocytic maturation of leukemic and normal myeloid precursors through a caspase dependent pathway. Blood 100:2421-2429.
35. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G. 2003. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and Erk pathways. Circulation 107:2250-2256.
36. Shankar DB, Cheng JC, Sakamoto KM. 2005. Role of Cyclic AMP response element binding protein in human leukemias. Cancer 104:1819-1824.
37. Shaywitz AJ, Greenberg ME. 1999. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68:821-861.
38. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A. 1997. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99:618-624.
39. Tucker SJ, Rae C, Littlejohn AF, Paul A, MacEwan DJ. 2004. Switching leukemia cell phenotype between life and death. Proc Natl Acad Sci USA 101:12940-12945.
40. Vinson CR, Sigler PB, McKnight SL. 1989. Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science 246:911-916.
41. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of PI-3-kinase 2-(4-morpholinyl-)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 18:5241-5248.
42. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163.
43. Weiner JA, Chun J. 1999. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc Natl Acad Sci USA 96:5233-5238.
44. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Davis-Smith T, Rauch C, Smith CA, Goodwin RG. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682.
45. Xing J, Ginty DD, Greenberg ME. 1996. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273:959-963.
46. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES, Guidotti L, Vitale M, Zauli G. 2000. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 95:3716-3724.
47. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P. 2003. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 92:732-740.
48. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D, Di Pietro R. 2005. PI-3K/Akt and NF-κB/IκB pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 202:900-911.